Editas Medicine: Pay

Editas Medicine paid its 3 named executives $4.4M in total in FY2025 (Dec). CEO Gilmore O’Neill, M.B., M.M.Sc. was paid $2.4M of that.

Pay$100 in the stock at the end of FY21 → $8
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Gilmore O’Neill, M.B., M.M.Sc.President and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Linda C. Burkly, Ph.D.Executive Vice President and Chief Scientific Officer
FY2025 (Dec)Not disclosed
FY2023 (Dec)
2 years
Amy ParisonSenior Vice President and Chief Financial Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $3.1M. The CEO of Editas Medicine was paid $2.4M, 24% below the median.

  1. 1Solid Biosciences
  2. 2Lyell Immunopharma
  3. 3Neurogene
  4. 4Nkarta
  5. 5Editas Medicine
  6. 6Fate Therapeutics
  7. 7Black Diamond Therapeutics
  8. 8Adicet Bio, Inc.Not disclosed
  9. 9Cabaletta BioNot disclosed
  10. 10Caribou BiosciencesNot disclosed
  11. 11Century TherapeuticsNot disclosed
  12. 12Generation Bio Co.Not disclosed
  13. 13Lexeo TherapeuticsNot disclosed
  14. 14Passage Bio, Inc.Not disclosed
  15. 15Precision BioSciences, Inc.Not disclosed
  16. 16Prime MedicineNot disclosed
  17. 17TScan Therapeutics, Inc.Not disclosed
  18. 18Tenaya Therapeutics, Inc.Not disclosed
  19. 19Verve Therapeutics, Inc.Not disclosed
  20. 20Vor BiopharmaNot disclosed
  21. 21Voyager, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.